In Q125, Cereno made tangible progress across both its clinical programmes. The period opened with new data for lead asset CS1 indicating disease-modifying signals, and was capped by FDA endorsement of the Phase IIb plan (May 2025). The next step will be an IND application for Phase IIb and we anti
